Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Tuesday the receipt of supply agreements for the delivery of COVID-19 Vaccine Moderna to the government of Taiwan and Colombia, respectively, in mid-2021.
Under the terms of the agreements, the company will supply five million doses to Taiwan and 10 million doses to Colombia, respectively.
Though the COVID-19 Vaccine Moderna is not currently approved for use in Taiwan or Colombia, the company will work with regulators to pursue necessary approvals prior to distribution.
The COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Center.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary